Lacosamide in the treatment of acute recurrent seizures and periodic epileptiform patterns in critically ill patients

Kimberly A. Parkerson, Claus Reinsberger, Sherry H. Chou, Barbara A. Dworetzky, Jong Woo Lee*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

31 Scopus citations

Abstract

We investigated the safety, tolerability, and effectiveness of lacosamide (LCM) in patients with acute recurrent seizures or with periodic epileptiform activity captured during continuous EEG monitoring. A total of 17 patients received LCM; 12 patients received LCM as a second or third antiepileptic drug (AED), one patient as a fourth AED, and one patient as a fifth AED. No additional AEDs were introduced after LCM in 15 patients. Twelve patients responded to LCM with improvement in the seizures or periodic epileptiform activity. Two patients required further AED management or burst suppression. No adverse effects, including symptomatic bradycardia and allergic reactions, were seen for intravenous infusion dosages up to 300. mg. Eleven patients were eventually discharged on LCM. LCM is an important new AED in the add-on treatment of acute recurrent seizures and periodic epileptiform activity in critically ill patients.

Original languageEnglish (US)
Pages (from-to)48-51
Number of pages4
JournalEpilepsy and Behavior
Volume20
Issue number1
DOIs
StatePublished - Jan 2011
Externally publishedYes

Keywords

  • Electroencephalography
  • Lacosamide
  • Periodic epileptiform activity
  • Seizure
  • Tolerability

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology
  • Behavioral Neuroscience

Fingerprint

Dive into the research topics of 'Lacosamide in the treatment of acute recurrent seizures and periodic epileptiform patterns in critically ill patients'. Together they form a unique fingerprint.

Cite this